NFXF Blog

A new study from the CDC and NFXF examines geographic access to Fragile X specialty care and identifies gaps in access to FXCRC clinics across the U.S.

Learn more about Mirum Pharmaceuticals, a biopharmaceutical company conducting clinical trials to investigate potential treatments for rare diseases.

New research uncovers how gene expression, protein regulation, and synaptic pathways are altered in Fragile X syndrome and FXTAS, offering deeper insight into disease biology.

Survey results reveal strong interest in gene therapy for Fragile X syndrome, highlighting family perspectives, hopes, concerns, and future research needs.

Children with Fragile X syndrome struggle more to process and recognize word patterns in speech. Scans show their auditory brain regions — specifically the primary auditory cortex — don’t sync with speech sounds as strongly as other children do.

Learn what recent federal actions related to Olmstead, the ADA, and Section 504 mean for individuals with disabilities and Fragile X families.

Our 2026 NFXF awards are in! Learn more about each award and the respective awardees.

Travel can feel overwhelming — especially when routines change, environments are different, and there is a lot of unexpected input happening around you. We pulled together some resources to support your next trip.

Updates about recent federal policy discussions and what they may mean for Fragile X research, healthcare, education, and support services.